GS-2121 + zimberelimab

GS-2121 + zimberelimab is an investigational combination therapy currently being assessed in a Phase 1 trial for adults with advanced solid tumors. GS-2121 is an orally administered small molecule antineoplastic agent under development by Gilead Sciences, while zimberelimab (also known as ZIM) is a fully human monoclonal antibody that targets PD-1 (programmed cell death protein 1), functioning as an immune checkpoint inhibitor. The rationale for combining these agents is the potential for immunomodulation or synergistic antitumor activity, typical of strategies employed in immuno-oncology. The precise mechanism of action and molecular targets of GS-2121 have not yet been publicly disclosed. Zimberelimab is well-characterized as an anti-PD-1 checkpoint inhibitor[1][2][3][5][6][7].

Other names

GS-2121GS2121GS 2121ZIM